FGFR4 and cancer: FGFR4, the key functional receptor of FGF17, is overexpressed in several cancers, including NSCLC, colorectal, breast, and hepatocellular carcinoma, and is closely linked to unfavorable patient outcomes (Lu et al., 2019; Chen et al., 2023; Braun et al., 2024).